Cargando…

(44)Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations

BACKGROUND: Recently, (44)Sc (T(1/2) = 3.97 h, Eβ(+) (av) = 632 keV, I = 94.3 %) has emerged as an attractive radiometal candidate for PET imaging using DOTA-functionalized biomolecules. The aim of this study was to investigate the potential of using NODAGA for the coordination of (44)Sc. Two pairs...

Descripción completa

Detalles Bibliográficos
Autores principales: Domnanich, Katharina A., Müller, Cristina, Farkas, Renata, Schmid, Raffaella M., Ponsard, Bernard, Schibli, Roger, Türler, Andreas, van der Meulen, Nicholas P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843811/
https://www.ncbi.nlm.nih.gov/pubmed/29564385
http://dx.doi.org/10.1186/s41181-016-0013-5
_version_ 1783305144002150400
author Domnanich, Katharina A.
Müller, Cristina
Farkas, Renata
Schmid, Raffaella M.
Ponsard, Bernard
Schibli, Roger
Türler, Andreas
van der Meulen, Nicholas P.
author_facet Domnanich, Katharina A.
Müller, Cristina
Farkas, Renata
Schmid, Raffaella M.
Ponsard, Bernard
Schibli, Roger
Türler, Andreas
van der Meulen, Nicholas P.
author_sort Domnanich, Katharina A.
collection PubMed
description BACKGROUND: Recently, (44)Sc (T(1/2) = 3.97 h, Eβ(+) (av) = 632 keV, I = 94.3 %) has emerged as an attractive radiometal candidate for PET imaging using DOTA-functionalized biomolecules. The aim of this study was to investigate the potential of using NODAGA for the coordination of (44)Sc. Two pairs of DOTA/NODAGA-derivatized peptides were investigated in vitro and in vivo and the results obtained with (44)Sc compared with its (68)Ga-labeled counterparts. DOTA-RGD and NODAGA-RGD, as well as DOTA-NOC and NODAGA-NOC, were labeled with (44)Sc and (68)Ga, respectively. The radiopeptides were investigated with regard to their stability in buffer solution and under metal challenge conditions using Fe(3+) and Cu(2+). Time-dependent biodistribution studies and PET/CT imaging were performed in U87MG and AR42J tumor-bearing mice. RESULTS: Both RGD- and NOC-based peptides with a DOTA chelator were readily labeled with (44)Sc and (68)Ga, respectively, and remained stable over at least 4 half-lives of the corresponding radionuclide. In contrast, the labeling of NODAGA-functionalized peptides with (44)Sc was more challenging and the resulting radiopeptides were clearly less stable than the DOTA-derivatized matches. (44)Sc-NODAGA peptides were clearly more susceptible to metal challenge than (44)Sc-DOTA peptides under the same conditions. Instability of (68)Ga-labeled peptides was only observed if they were coordinated with a DOTA in the presence of excess Cu(2+). Biodistribution data of the (44)Sc-labeled peptides were largely comparable with the data obtained with the (68)Ga-labeled counterparts. It was only in the liver tissue that the uptake of (68)Ga-labeled DOTA compounds was markedly higher than for the (44)Sc-labeled version and this was also visible on PET/CT images. The (44)Sc-labeled NODAGA-peptides showed a similar tissue distribution to those of the DOTA peptides without any obvious signs of in vivo instability. CONCLUSIONS: Although DOTA revealed to be the preferred chelator for stable coordination of (44)Sc, the data presented in this work indicate the possibility of using NODAGA in combination with (44)Sc. In view of a clinical study, thorough investigations will be necessary regarding the labeling conditions and storage solutions in order to guarantee sufficient stability of (44)Sc-labeled NODAGA compounds. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s41181-016-0013-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5843811
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-58438112018-03-19 (44)Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations Domnanich, Katharina A. Müller, Cristina Farkas, Renata Schmid, Raffaella M. Ponsard, Bernard Schibli, Roger Türler, Andreas van der Meulen, Nicholas P. EJNMMI Radiopharm Chem Research BACKGROUND: Recently, (44)Sc (T(1/2) = 3.97 h, Eβ(+) (av) = 632 keV, I = 94.3 %) has emerged as an attractive radiometal candidate for PET imaging using DOTA-functionalized biomolecules. The aim of this study was to investigate the potential of using NODAGA for the coordination of (44)Sc. Two pairs of DOTA/NODAGA-derivatized peptides were investigated in vitro and in vivo and the results obtained with (44)Sc compared with its (68)Ga-labeled counterparts. DOTA-RGD and NODAGA-RGD, as well as DOTA-NOC and NODAGA-NOC, were labeled with (44)Sc and (68)Ga, respectively. The radiopeptides were investigated with regard to their stability in buffer solution and under metal challenge conditions using Fe(3+) and Cu(2+). Time-dependent biodistribution studies and PET/CT imaging were performed in U87MG and AR42J tumor-bearing mice. RESULTS: Both RGD- and NOC-based peptides with a DOTA chelator were readily labeled with (44)Sc and (68)Ga, respectively, and remained stable over at least 4 half-lives of the corresponding radionuclide. In contrast, the labeling of NODAGA-functionalized peptides with (44)Sc was more challenging and the resulting radiopeptides were clearly less stable than the DOTA-derivatized matches. (44)Sc-NODAGA peptides were clearly more susceptible to metal challenge than (44)Sc-DOTA peptides under the same conditions. Instability of (68)Ga-labeled peptides was only observed if they were coordinated with a DOTA in the presence of excess Cu(2+). Biodistribution data of the (44)Sc-labeled peptides were largely comparable with the data obtained with the (68)Ga-labeled counterparts. It was only in the liver tissue that the uptake of (68)Ga-labeled DOTA compounds was markedly higher than for the (44)Sc-labeled version and this was also visible on PET/CT images. The (44)Sc-labeled NODAGA-peptides showed a similar tissue distribution to those of the DOTA peptides without any obvious signs of in vivo instability. CONCLUSIONS: Although DOTA revealed to be the preferred chelator for stable coordination of (44)Sc, the data presented in this work indicate the possibility of using NODAGA in combination with (44)Sc. In view of a clinical study, thorough investigations will be necessary regarding the labeling conditions and storage solutions in order to guarantee sufficient stability of (44)Sc-labeled NODAGA compounds. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s41181-016-0013-5) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-05-05 /pmc/articles/PMC5843811/ /pubmed/29564385 http://dx.doi.org/10.1186/s41181-016-0013-5 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Domnanich, Katharina A.
Müller, Cristina
Farkas, Renata
Schmid, Raffaella M.
Ponsard, Bernard
Schibli, Roger
Türler, Andreas
van der Meulen, Nicholas P.
(44)Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations
title (44)Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations
title_full (44)Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations
title_fullStr (44)Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations
title_full_unstemmed (44)Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations
title_short (44)Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations
title_sort (44)sc for labeling of dota- and nodaga-functionalized peptides: preclinical in vitro and in vivo investigations
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843811/
https://www.ncbi.nlm.nih.gov/pubmed/29564385
http://dx.doi.org/10.1186/s41181-016-0013-5
work_keys_str_mv AT domnanichkatharinaa 44scforlabelingofdotaandnodagafunctionalizedpeptidespreclinicalinvitroandinvivoinvestigations
AT mullercristina 44scforlabelingofdotaandnodagafunctionalizedpeptidespreclinicalinvitroandinvivoinvestigations
AT farkasrenata 44scforlabelingofdotaandnodagafunctionalizedpeptidespreclinicalinvitroandinvivoinvestigations
AT schmidraffaellam 44scforlabelingofdotaandnodagafunctionalizedpeptidespreclinicalinvitroandinvivoinvestigations
AT ponsardbernard 44scforlabelingofdotaandnodagafunctionalizedpeptidespreclinicalinvitroandinvivoinvestigations
AT schibliroger 44scforlabelingofdotaandnodagafunctionalizedpeptidespreclinicalinvitroandinvivoinvestigations
AT turlerandreas 44scforlabelingofdotaandnodagafunctionalizedpeptidespreclinicalinvitroandinvivoinvestigations
AT vandermeulennicholasp 44scforlabelingofdotaandnodagafunctionalizedpeptidespreclinicalinvitroandinvivoinvestigations